iCo Therapeutics iCo Therapeutics Inc.

  • Home
  • Corporate Overview
    • Overview
    • Partnering Strategy
    • Management Team
    • Board of Directors
    • Strategic Advisory Board
    • Professional Advisors
  • Pipeline
    • iCo-007
    • Antisense Technology
    • iCo-008
    • iCo-009
    • Clinical Trials
  • Investor Relations
    • Overview
    • Press Releases
    • Media Coverage
    • Upcoming Events
  • Careers
    • About Vancouver
    • Current Opportunities
  • Contact Us

Corporate Overview

Overview

iCo Therapeutics is a “Search and Development” company. By focusing efforts on development instead of research, iCo’s business model aims to acquire the rights to drugs that are either off-patent, currently approved or near commercialization and develop them by redosing or reformulating them for new or expanded labels. Subsequent development by iCo of these therapeutics may include drug delivery technologies—such as sustained release, biodegradable matrices, etc to extend patent coverage.

There is a significant decrease in development risk associated with targeting existing drugs, including:

  • Reduced risk of adverse events since clinical testing and systemic use in humans has already been established.
  • Scale-up and manufacturing issues have already been addressed since clinical grade material has been made.
  • The target and mechanism of action has been identified.

 

corporate overview Formulations vs New Chemical Entity

 

  • Home
  • Corporate Overview
  • Pipeline
  • Investor Relations
  • Careers
  • Contact Us

Copyright © 2005 iCo Therapeutics Inc. All rights reserved. Terms of Use.